OCUL.US Ocular Therapeutix Inc

Healthcare Pharmaceuticals USA Stocks
6.21 USD
Close of Nov 15, 2026
5.94 16.44
Market cap
USD 1.37B
P/E
-
P/B
3.09x
ROE
-79.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OCUL.US undervalued?

Graham number

The Graham number of Ocular Therapeutix Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ocular Therapeutix Inc fundamental analysis

No fundamental analysis for Ocular Therapeutix Inc yet.

Ocular Therapeutix Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravi…

Full company profile